NCT05605665

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögren's Syndrome

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose IL-2 combined with rapamycin in the treatment of Sjogren's syndrome

Detailed description

A randomized, open clinical trial was designed. Patients will be randomly divided into three groups，including Ld-IL2 group, rapamycin group, Ld-IL2+rapamycin group. The improvement of clinical and laboratory indexes will be evaluated. Changes of immune cell subsets and cytokines will be monitored.

Conditions

• Sjögren's Syndrome

Interventions

Type	Name	Description
DRUG	low-dose interleukin-2	low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
DRUG	rapamycin	Rapamycin 0.5ml was taken orally once per day

Timeline

• Start date: 2022-12-05
• Primary completion: 2023-12-30
• Completion: 2024-03-31
• First posted: 2022-11-04
• Last updated: 2024-07-09

Locations

1 site across 1 country: China